论文部分内容阅读
目的探讨双环醇治疗非酒精性脂肪性肝炎(NASH)的临床疗效及安全性。方法 136例NASH患者随机分为治疗组72例与对照组64例。两组均在适当休息、控制饮食、降低体重的基础上,治疗组服用双环醇片25mg,Tid,疗程6月;对照组服用水飞蓟宾70mg,Tid,疗程6月。观察两组治疗前后患者症状、肝脏彩超及血生化指标变化。结果治疗组肝区不适、纳差、乏力、腹胀改善情况优于对照组(P<0.05),两组均能明显降低ALT、AST、TC、LDL-C、FBG并减轻肝脏彩超脂肪变性,但在降低TG、GGT方面治疗组优于对照组(P<0.05)。结论双环醇能有效改善NASH患者的临床症状、血生化指标及其肝脏影像学表现,临床应用过程中未发生明显不良反应。
Objective To investigate the clinical efficacy and safety of bicyclol in the treatment of non-alcoholic steatohepatitis (NASH). Methods A total of 136 NASH patients were randomly divided into treatment group (72 cases) and control group (64 cases). On the basis of proper rest, diet control and weight reduction, the treatment group took bicyclol 25mg and Tid for 6 months. The control group took silibinin 70mg and Tid for 6 months. Before and after treatment in patients with symptoms, liver color Doppler ultrasound and blood biochemistry changes. Results The improvement of hepatic discomfort, anorexia, fatigue and bloating in the treatment group was better than that in the control group (P <0.05). Both of the two groups could significantly reduce ALT, AST, TC, LDL-C and FBG, The treatment group was better than the control group in reducing TG and GGT (P <0.05). Conclusion Bicyclol can effectively improve the clinical symptoms, blood biochemical markers and liver imaging findings in patients with NASH. There are no obvious adverse reactions in clinical application.